The Breast
Volume 19, Issue 2 , Pages 92-96 , April 2010

Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy

  • Stephanie L. Hines

      Affiliations

    • Mayo Clinic Florida, Jacksonville, FL 32224, USA
    • Corresponding Author InformationCorresponding author at: Mayo Clinic Florida, Breast Center, 4500 San Pablo Road, Jacksonville, FL 32224, USA. Tel.: +1 904 953 0707; fax: +1 904 953 1412.
    • ,
  • Jeff A. Sloan

      Affiliations

    • Mayo Clinic Rochester, Rochester, MN 55905, USA
    • ,
  • Pamela J. Atherton

      Affiliations

    • Mayo Clinic Rochester, Rochester, MN 55905, USA
    • ,
  • Edith A. Perez

      Affiliations

    • Mayo Clinic Florida, Jacksonville, FL 32224, USA
    • ,
  • Shaker R. Dakhil

      Affiliations

    • Wichita Community Clinical Oncology, Wichita, KS 67214-3882, USA
    • ,
  • David B. Johnson

      Affiliations

    • Wichita Community Clinical Oncology, Wichita, KS 67214-3882, USA
    • ,
  • Pavan S. Reddy

      Affiliations

    • Wichita Community Clinical Oncology, Wichita, KS 67214-3882, USA
    • ,
  • Robert J. Dalton

      Affiliations

    • Immanuel-St. Joseph Hospital Mayo Health System, Mankato, MN 56002, USA
    • ,
  • Bassam I. Mattar

      Affiliations

    • Wichita Community Clinical Oncology, Wichita, KS 67214-3882, USA
    • ,
  • Charles L. Loprinzi

      Affiliations

    • Mayo Clinic Rochester, Rochester, MN 55905, USA

Received 19 June 2009 ,Revised 30 November 2009 ,Accepted 1 December 2009.

References 

  1. Perez EA, Weilbaecher K. Aromatase inhibitors and bone loss. Oncology. 2006;20(9):1029–1039
  2. Prince RL, Smith M, Dick IM, Price RI, Webb PG, Henderson NK, et al. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone replacement therapy. NEJM. 1991;325(17):1189–1195
  3. Riis B, Thomsen K, Christiansen C. Does calcium supplementation prevent postmenopausal bone loss? A double-blind, controlled clinical study. NEJM. 1987;316(4):173–177
  4. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333
  5. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004 Apr 14;291(14):1701–1712
  6. Powles T, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 1996;14(1):78–84
  7. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopasual women with primary breast cancer. NEJM. 2004;350(11):1081–1092
  8. The ATAC. Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131–2139
  9. The ATAC. Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45–53
  10. Coates AS. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. JCO. 2007;25(5):486–492
  11. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, et al. Survival and safety of exemestane versus tamoxifen after 2–3years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet. 2007;369:559–570
  12. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from the NCIC CTG MA.17. JNCI. 2005;97(17):1262–1271
  13. Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the anastrozole, tamoxifen, alone or in combination trial. J Bone Mineral Res. 2006;21(8):1215–1223
  14. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24(22):3629–3635
  15. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol. 2007;25(7):829–836
  16. Reid IR, Brown JP, Burckhardt P, Horowitz A, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. NEJM. 2002;346(9):653–661
  17. Hines SL, Mincey BA, Dentchev T, Sloan JA, Perez EA, Johnson DB, et al. Immediate vs. delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen. Breast Cancer Res Treat. 2009;DOI 10.1007/s10549-009-0332-2
  18. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72–75
  19. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19(4):385–397
  20. Harrington JT, Ste-Marie LG, Brandi ML, Civitelli R, Fardellone P, Grauer A, et al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;74:129–135
  21. Watts NB, Cooper C, Lindsay R, Eastell R, Manhart MD, Barton IP, et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. J Clin Densitom. 2004;7(3):255–261
  22. Crandall C. Risedronate: a clinical review. Arch Intern Med. 2001;161:353–360
  23. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280(24):2077–2082
  24. Van Poznak C, Hannon RA, Clack G, Campone M, Mackey JR, Apffelstaedt J, et al. The SABRE (Study of Anastrozole with the Bisphosphonate Risedronate) study: 12-month analysis. Breast Cancer Res Treat. 2007;106(Supple 1):S37;(abstract 502)
  25. Lester JE, Dodwell D, Purohit OP, Gutcher SA, Ellis SP, Thorpe R, et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res. 2008;14(19):6336–6342

☆ This study was conducted as a trial of the Mayo Cancer Center Research Consortium in part by Public Health Service grants CA-35431, CA-35195, and CA-52352. The content is solely the responsibility of the authors and does not necessarily represent the views of the National Cancer Institute or the National Institute of Health.

☆☆ Additional participating institutions include: Carle Cancer Center CCOP, Urbana, IL 61801 (Kendrith M. Rowland, Jr.); Cedar Rapids Oncology Project CCOP, Cedar Rapids, IA 52403 (Martin Wiesenfeld).

PII: S0960-9776(09)00173-8

doi: 10.1016/j.breast.2009.12.001

The Breast
Volume 19, Issue 2 , Pages 92-96 , April 2010

Article Tools

* Image Usage & Resolution